The modified STONE scoring system enhances diagnostic accuracy by including five parameters gender, pain duration, hematuria, history of urinary stones, and C-reactive protein (CRP) levels and stratifies patients into low (0–4), moderate (5–9), and high (10–16) risk categories, demonstrating improved performance with an AUC (Area Under the Curve) of 0.94 in the original cohort and consistent external validation across various populations, while aligning with contemporary biomarker-based triage strategies [11,12]. The gene discussed is CRP; the disease is urolithiasis.